This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Procter & Gamble (PG) Up 11.5% in Three Months: Here's Why
by Zacks Equity Research
Although high costs and negative currency impacts remain near-term headwinds for Procter & Gamble (PG), robust pricing and productivity plans are likely to be beneficial.
Beat the Market Like Zacks: Novo Nordisk, Microsoft, Clorox in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Here's Why You Should Invest in Clorox (CLX) Right Away
by Zacks Equity Research
Despite inflation concerns, Clorox (CLX) looks well-poised to drive growth in the future on the back of solid demand, pricing actions, cost-saving efforts and other growth strategies.
Colgate (CL) Rises 5% in the Past Three Months: Here's How
by Zacks Equity Research
Despite rising raw material costs, Colgate's (CL) robust innovation and expansion plans are likely to drive growth in the long term.
Monster Beverage (MNST) Tops Q1 Earnings & Sales Estimates
by Zacks Equity Research
Monster Beverage's (MNST) Q1 results reflect gains from a strong brand performance, innovation, product launches and pricing actions amid elevated costs.
Church & Dwight (CHD) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Church & Dwight (CHD) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights Coty, Church & Dwight, Hershey and Portland General Electric
by Zacks Equity Research
Coty, Church & Dwight, Hershey and Portland General Electric are included in this Analyst Blog.
Church & Dwight (CHD) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 Top Recession-Proof Stocks That Are Worth a Buy Right Away
by Tirthankar Chakraborty
Invest in stocks such as Coty (COTY), Church & Dwight (CHD), Hershey (HSY) & Portland General Electric (POR) since demand for their products remains unaffected amid an economic downturn.
Clorox (CLX) Beats Q3 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Clorox's (CLX) Q3 results reflect gains from a solid product pipeline, improved pricing, cost savings and strong execution, offset by lower volume and higher commodity costs.
Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Church & Dwight (CHD) Q1 Earnings Top Estimates, Increase Y/Y
by Zacks Equity Research
Church & Dwight's (CHD) first-quarter top and bottom lines increase year over year, driven by the strong consumer demand for its products.
Here's What Key Metrics Tell Us About Church & Dwight (CHD) Q1 Earnings
by Zacks Equity Research
Although the revenue and EPS for Church & Dwight (CHD) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Church & Dwight (CHD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Church & Dwight (CHD) delivered earnings and revenue surprises of 11.84% and 5.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Church & Dwight (CHD) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Church & Dwight's (CHD) first-quarter 2023 results are likely to reflect profit from strong consumer demand. It is likely to reflect benefits from strong pricing action incurred to counter inflation.
Colgate-Palmolive (CL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Colgate-Palmolive (CL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Procter & Gamble (PG) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
P&G (PG) delivered earnings and revenue surprises of 3.79% and 4.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Church & Dwight (CHD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Church & Dwight (CHD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Church & Dwight (CHD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Church & Dwight (CHD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Will Strong Brand Portfolio Aid Church & Dwight's (CHD) Growth?
by Zacks Equity Research
Church & Dwight's (CHD) pricing efforts, buyouts and favorable demand act as upsides against macroeconomic headwinds.
Zacks Industry Outlook Highlights The Procter & Gamble, Colgate-Palmolive, Henkel AG, Church & Dwight and The Clorox
by Zacks Equity Research
The Procter & Gamble, Colgate-Palmolive, Henkel AG, Church & Dwight and The Clorox are part of the Zacks Industry Outlook article.
5 Soaps & Cleaning Materials Stocks to Watch as Industry Catches Pace
by Rajani Lohia
The soap and cleaning materials industry looks poised for growth on robust demand, pricing initiatives, innovation, digital transformation and brand building, while elevated costs remain headwinds. Players like PG, CL, HENKY, CHD and CLX seem well-poised.
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Take the Zacks Approach to Beat the Market: Ulta Beauty, Clorox, Similarweb in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.